drugset / Trial / NCT03184194
Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide
Phase 2
Completed
62 enrolled
Amsterdam UMC, location VUmc
Albert Schweitzer Hospital · collabErasmus Medical Center · collabIsala · collabMaastricht University Medical Center · collabMeander Medical Center · collabRadboud University Medical Center · collabRijnstate Hospital · collabSt. Antonius Hospital · collabUMC Utrecht · collabUniversity Medical Center Groningen · collab
RandomizedSequentialOpen-labelTreatment
Summary
Evaluation of the effect of nivolumab and daratumumab with or without low-dose cyclophosphamide in patients with relapsed/refractory multiple myeloma.
Timeline
- Start
- 2018-02-21
- Primary completion
- 2023-01-25
- Completion
- 2024-01-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 50 mg | — |
| Subject | Daratumumab | Monoclonal antibody | 16 mg/kg | — |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | — |